Long-acting amylin analogue
Cagrilintide
- that reduces food intake and slows gastric emptying; often studied with GLP-1 agonists.
Primary Mechanism of Action
Clinical / Scientific
Cagrilintide is a long-acting analogue activating AMY receptors (calcitonin- core with RAMPs). Central satiety signalling and delayed gastric emptying reduce energy intake in clinical development programmes. It is investigational in many markets.
Pathway Targets
Amylin receptors
Scientific explanation
Agonism reducing intake and gastric emptying.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Amylin receptors
Mechanistically Relevant Repurposed & Adjunctive Applications
Obesity / metabolic development programmes
InvestigationalMechanistic rationale
Clinical-stage analogue, including combinations with semaglutide. Not automatically a locally labelled product.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| AMY receptors | Agonism | Satiety / gastric emptying | Investigational |
Potential Adjunctive Contexts
Mechanistic complementarity with GLP-1 agonists (for example semaglutide) is the basis of co-development, because and GLP-1 act on overlapping but distinct satiety circuits.
Mechanistic Interaction Considerations
Additive gastrointestinal slowing and glucose-lowering with incretins. Not for unmonitored combination with other delayed-gastric-emptying drugs without clinical oversight.
In Plain Language
Cagrilintide copies , a hormone from the pancreas that helps you feel full and slows how fast the stomach empties.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.